627 related articles for article (PubMed ID: 30643947)
1. Routinely staging gastric cancer with
Findlay JM; Antonowicz S; Segaran A; El Kafsi J; Zhang A; Bradley KM; Gillies RS; Maynard ND; Middleton MR
Eur Radiol; 2019 May; 29(5):2490-2498. PubMed ID: 30643947
[TBL] [Abstract][Full Text] [Related]
2. Restaging oesophageal cancer after neoadjuvant therapy with (18)F-FDG PET-CT: identifying interval metastases and predicting incurable disease at surgery.
Findlay JM; Gillies RS; Franklin JM; Teoh EJ; Jones GE; di Carlo S; Gleeson FV; Maynard ND; Bradley KM; Middleton MR
Eur Radiol; 2016 Oct; 26(10):3519-33. PubMed ID: 26883329
[TBL] [Abstract][Full Text] [Related]
3. Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence.
Findlay JM; Dickson E; Fiorani C; Bradley KM; Mukherjee S; Gillies RS; Maynard ND; Middleton MR
Eur Radiol; 2019 Dec; 29(12):6717-6727. PubMed ID: 31278574
[TBL] [Abstract][Full Text] [Related]
4. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?
Cuellar SL; Carter BW; Macapinlac HA; Ajani JA; Komaki R; Welsh JW; Lee JH; Swisher SG; Correa AM; Erasmus JJ; Hofstetter WL
J Thorac Oncol; 2014 Aug; 9(8):1202-6. PubMed ID: 25157774
[TBL] [Abstract][Full Text] [Related]
5. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT.
Yun M; Lim JS; Noh SH; Hyung WJ; Cheong JH; Bong JK; Cho A; Lee JD
J Nucl Med; 2005 Oct; 46(10):1582-8. PubMed ID: 16204706
[TBL] [Abstract][Full Text] [Related]
6. Significance of CT attenuation and F-18 fluorodeoxyglucose uptake of visceral adipose tissue for predicting survival in gastric cancer patients after curative surgical resection.
Lee JW; Son MW; Chung IK; Cho YS; Lee MS; Lee SM
Gastric Cancer; 2020 Mar; 23(2):273-284. PubMed ID: 31485803
[TBL] [Abstract][Full Text] [Related]
7.
Lehmann K; Eshmuminov D; Bauerfeind P; Gubler C; Veit-Haibach P; Weber A; Abdul-Rahman H; Fischer M; Reiner C; Schneider PM
Eur J Surg Oncol; 2017 Jan; 43(1):196-202. PubMed ID: 27692533
[TBL] [Abstract][Full Text] [Related]
8. The impact of baseline
Foley KG; Coomer W; Coles B; Bradley KM
Br J Radiol; 2022 Oct; 95(1139):20220437. PubMed ID: 36129138
[TBL] [Abstract][Full Text] [Related]
9. Significance of baseline FDG-PET/CT scan as a method of staging regional lymph nodes in patients with operable distal oesophageal or gastroesophageal junction adenocarcinoma.
Papaxoinis G; Weaver JMJ; Khoja L; Patrao A; Stamatopoulou S; Alchawaf A; Owen-Holt V; Germetaki T; Kordatou Z; Mansoor W
Acta Oncol; 2017 Sep; 56(9):1224-1232. PubMed ID: 28524708
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.
Hogan MP; Goldman DA; Dashevsky B; Riedl CC; Gönen M; Osborne JR; Jochelson M; Hudis C; Morrow M; Ulaner GA
J Nucl Med; 2015 Nov; 56(11):1674-80. PubMed ID: 26294295
[TBL] [Abstract][Full Text] [Related]
11. The peak-standardized uptake value (P-SUV) by preoperative positron emission tomography-computed tomography (PET-CT) is a useful indicator of lymph node metastasis in gastric cancer.
Oh HH; Lee SE; Choi IS; Choi WJ; Yoon DS; Min HS; Ra YM; Moon JI; Kang YH
J Surg Oncol; 2011 Oct; 104(5):530-3. PubMed ID: 21618250
[TBL] [Abstract][Full Text] [Related]
12. Intra-tumor metabolic heterogeneity of gastric cancer on
Liu G; Yin H; Cheng X; Wang Y; Hu Y; Liu T; Shi H
Clin Exp Med; 2021 Feb; 21(1):129-138. PubMed ID: 32880779
[TBL] [Abstract][Full Text] [Related]
13. PET/CT in breast cancer staging is useful for evaluation of axillary lymph node and distant metastases.
Davidson T; Shehade N; Nissan E; Sklair-Levy M; Ben-Haim S; Barshack I; Zippel D; Halevy A; Chikman B
Surg Oncol; 2021 Sep; 38():101567. PubMed ID: 33866190
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial.
Verghote F; Poppe L; Verbeke S; Dirix P; Albersen M; De Meerleer G; Berghen C; Ost P; Villeirs G; De Visschere P; De Man K; De Maeseneer D; Rottey S; Van Praet C; Decaestecker K; Fonteyne V
BMC Cancer; 2021 Oct; 21(1):1113. PubMed ID: 34663254
[TBL] [Abstract][Full Text] [Related]
15. DaPeCa-7: comparative assessment of fluorodeoxyglucose positron emission tomography/computed tomography (CT) and conventional diagnostic CT in diagnosis of lymph node metastases, distant metastases and incidental findings in patients with invasive penile cancer.
Jakobsen JK; Frahm Nielsen T; Ipsen P; Albrecht-Beste E; Cardoso Costa J; Alslev L; Predbjørn Krarup K; Grønkaer Toft B; Høyer S; Bouchelouche K; Bjerggaard Jensen J
BJU Int; 2021 Feb; 127(2):254-262. PubMed ID: 33448605
[TBL] [Abstract][Full Text] [Related]
16. Should 18F-FDG PET/CT Be Routinely Performed in the Clinical Staging of Locally Advanced Gastric Adenocarcinoma?
Perlaza P; Ortín J; Pagès M; Buxó E; Fernández-Esparrach G; Colletti PM; Rubello D; Mayoral M; Sánchez N; Ruiz C; Ginés A; Fuster D
Clin Nucl Med; 2018 Jun; 43(6):402-410. PubMed ID: 29485442
[TBL] [Abstract][Full Text] [Related]
17. Primary Tumor ¹⁸F-FDG Avidity Affects the Performance of ¹⁸F-FDG PET/CT for Detecting Gastric Cancer Recurrence.
Kim SJ; Cho YS; Moon SH; Bae JM; Kim S; Choe YS; Kim BT; Lee KH
J Nucl Med; 2016 Apr; 57(4):544-50. PubMed ID: 26678615
[TBL] [Abstract][Full Text] [Related]
18. PET/CT with
Teixeira SC; Koolen BB; Elkhuizen PH; Vrancken Peeters MT; Stokkel MP; Rodenhuis S; van der Noort V; Rutgers EJ; Valdés Olmos RA
Eur J Surg Oncol; 2017 Apr; 43(4):625-635. PubMed ID: 27847287
[TBL] [Abstract][Full Text] [Related]
19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
20. Has integrated 18F FDG PET/CT improved staging, reduced early recurrence or increased survival in oesophageal cancer?
Torrance AD; Almond LM; Fry J; Wadley MS; Lyburn ID
Surgeon; 2015 Feb; 13(1):19-33. PubMed ID: 24206935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
